Export 100 results:
[ Author(Asc)] Title Type Year
Filters: First Letter Of Last Name is F  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
F
S. L. Furth, Sullivan, E. K., Neu, A. M., Tejani, A., and Fivush, B. A., Varicella in the first year after renal transplantation: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS)., Pediatr Transplant, vol. 1, no. 1, pp. 37-42, 1997.
S. L. Furth, Stablein, D., Fine, R. N., Powe, N. R., and Fivush, B. A., Adverse clinical outcomes associated with short stature at dialysis initiation: a report of the North American Pediatric Renal Transplant Cooperative Study., Pediatrics, vol. 109, no. 5, pp. 909-13, 2002.
S. L. Furth, Stablein, D., Fine, R. N., Powe, N. R., and Fivush, B. A., Adverse clinical outcomes associated with short stature at dialysis initiation: a report of the North American Pediatric Renal Transplant Cooperative Study, Pediatrics, vol. 109, pp. 909-13, 2002.
S. L. Furth, Neu, A. M., Sullivan, E. K., Gensler, G., Tejani, A., and Fivush, B. A., Immunization practices in children with renal disease: a report of the North American Pediatric Renal Transplant Cooperative Study., Pediatr Nephrol, vol. 11, no. 4, pp. 443-6, 1997.
K. Fullmer, Kim, J., Oden, N., and Thompson, D. J. S., Electronic Monitoring of Data Quality Using the "Contradiction Density", 2004.
M. Frogel, Nerwen, C., Cohen, A., VanVeldhuisen, P., Harrington, M., and Boron, M., Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry., J Perinatol, vol. 28, no. 7, pp. 511-7, 2008.
M. Frogel, Nerwen, C., Boron, M., Cohen, A., VanVeldhuisen, P., Harrington, M., and Groothuis, J., Improved outcomes with home-based administration of palivizumab: results from the 2000-2004 Palivizumab Outcomes Registry., Pediatr Infect Dis J, vol. 27, no. 10, pp. 870-3, 2008.
M. P. Frogel, Nerwen, C., Boron, M. L., Cohen, A. H., Rankin, N. M., and Group, thePalivizuma, Compliance with needle length guidelines for palivizumab administration: preliminary survey results from the 2003-2004 Palivizumab Outcomes Registry Investigators, 2004.
M. Frogel, Nerwen, C., Boron, M., Cohen, A., Van Veldhuisen, P., Harrington, M., and Group, P. Outcomes R., Prevention of Hospitalization Due to Respiratory Syncytial Virus: Results from the Palivizumab Outcomes Registry, J Perinatol, vol. 28, pp. 511-517, 2008.
M. Frogel, Nerwen, C., Boron, M., Cohen, A., Van Veldhuisen, P., Harrington, M., and Group, P. Outcomes R., Improved Outcomes with Home-Based Administration of Palivizumab: Results from the 2000-2004 Palivizumab Outcomes Registry, J Perinatol, vol. 28, pp. 511-517, 2008.
D. A. J. Friedman-Klabanoff, Berry, A. A., Travassos, M. A., Cox, C., Zhou, Y., Mo, A. X., Nomicos, E. Y. H., Deye, G. A., Pasetti, M. F., and Laurens, M. B., Low dose recombinant full-length circumsporozoite protein-based Plasmodium falciparum vaccine is well-tolerated and highly immunogenic in phase 1 first-in-human clinical testing., Vaccine, vol. S0264-410X(20)31590, 2021.
T. R. Friberg, Chew, E., Clemons, T. E., Bressler, S., and Group, A. - R. Eye Diseas, The Effect of AREDS Supplementation on Visual Acuity Loss in Eyes with Advanced AMD, in Meeting, Association for Research in Vision and Ophthalmology (ARVO), Fort Lauderdale, FL, 2005.
S. Frey, Houghton, M., Coates, S., Abrignani, S., Chien, D., Rosa, D., Pileri, P., Ray, R., Di Bisceglie, A., Rinella, P., Hill, H., Wolff, M., Schultze, V., Han, J., Scharschmidt, B., and Belshe, R., Safety and Immunogenicity of HCV E1E2 Vaccine Adjuvanted with MF59 Administered to Healthy Adults, Vaccine, vol. 28, pp. 6367-6373, 2010.
S. E. Frey, Bernstein, D. I., Gerber, M. A., Keyserling, H. L., Munoz, F. M., Winokur, P. L., Turley, C. B., Rupp, R. E., Hill, H., Wolff, M., Noah, D. L., Ross, A. C., Cress, G., and Belshe, R. B., Safety and immune responses in children after concurrent or sequential 2009 H1N1 and 2009-2010 seasonal trivalent influenza vaccinations., J Infect Dis, vol. 206, no. 6, pp. 828-37, 2012.
S. E. Frey, Winokur, P. L., Hill, H., Goll, J. B., Chaplin, P., and Belshe, R. B., Phase II randomized, double-blinded comparison of a single high dose (5×10(8) TCID50) of modified vaccinia Ankara compared to a standard dose (1×10(8) TCID50) in healthy vaccinia-naïve individuals., Vaccine, vol. 32, no. 23, pp. 2732-9, 2014.
S. E. Frey, Bernstein, D. I., Brady, R. C., Keitel, W. A., Sahly, H. E., Rouphael, N. G., Mulligan, M. J., Atmar, R. L., Edupuganti, S., Patel, S. M., Dickey, M., Graham, I., Anderson, E. L., Noah, D. L., Hill, H., Wolff, M., and Belshe, R. B., Phase II Trial in Adults of Concurrent or Sequential 2009 Pandemic H1N1 and 2009-2010 Seasonal Trivalent Influenza Vaccinations, Vaccine, vol. 33, pp. 163-173, 2015.
S. E. Frey, Wald, A., Edupuganti, S., Jackson, L. A., Stapleton, J. T., Sahly, H. El, El-Kamary, S. S., Edwards, K., Keyserling, H., Winokur, P., Keitel, W., Hill, H., Goll, J. B., Anderson, E. L., Graham, I. L., Johnston, C., Mulligan, M., Rouphael, N., Atmar, R., Patel, S., Chen, W., Kotloff, K., C Creech, B., Chaplin, P., and Belshe, R. B., Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects., Vaccine, vol. 33, no. 39, pp. 5225-34, 2015.
S. E. Frey, Bernstein, D. I., Gerber, M. A., Keyserling, H. L., Munoz, F. M., Winokur, P. L., Turley, C. B., Rupp, R. E., Hill, H., Wolff, M., Noah, D. L., Ross, A. C., Cress, G., and Belshe, R. B., Safety and Immune Responses in Children After Concurrent or Sequential 2009 H1N1 and 2009-2010 Seasonal Trivalent Influenza Vaccinations, J Infect Dis, vol. 206, pp. 828-837, 2012.
S. E. Frey, Bernstein, D. I., Brady, R. C., Keitel, W. A., Sahly, H. El, Rouphael, N. Georges, Mulligan, M. J., Atmar, R. L., Edupuganti, S., Patel, S. M., Dickey, M., Graham, I., Anderson, E. L., Noah, D. L., Hill, H., Wolff, M., and Belshe, R. B., Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations., Vaccine, vol. 33, no. 1, pp. 163-73, 2015.
S. E. Frey, Winokur, P. L., Hill, H., Goll, J. B., Chaplin, P., and Belshe, R. B., Phase II Randomized, Double-Blinded Comparison of a Single High Dose (5×10(8) TCID 50) of Modified Vaccinia Ankara Compared to a Standard Dose (1×10(8) TCID50) in Healthy Vaccinia-Naïve Individuals, Vaccine, vol. 32, pp. 2732-2739, 2014.
S. E. Frey, Stapleton, J. T., Ballas, Z. K., Rasmussen, W. L., Kaufman, T. M., Blevins, T., Jensen, T. L., D Davies, H., Tary-Lehman, M., Chaplin, P., Hill, H., and Goll, J. B., Human antibody responses following vaccinia immunization using protein microarrays and correlation with cell-mediated and antibody dependent cellular cytotoxicity responses., J Infect Dis, 2021.
S. E. Frey, Houghton, M., Coates, S., Abrignani, S., Chien, D., Rosa, D., Pileri, P., Ray, R., Di Bisceglie, A. M., Rinella, P., Hill, H., Wolff, M. C., Schultze, V., Han, J. H., Scharschmidt, B., and Belshe, R. B., Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults., Vaccine, vol. 28, no. 38, pp. 6367-73, 2010.
R. W. Frenck, Baqar, S., Alexander, W., Dickey, M., McNeal, M., El-Khorazaty, J., Baughman, H., Hoeper, A., Barnoy, S., Suvarnapunya, A. E., Kaminski, R. W., and Venkatesan, M. M., A Phase I trial to evaluate the safety and immunogenicity of WRSs2 and WRSs3; two live oral candidate vaccines against Shigella sonnei., Vaccine, vol. 36, no. 32 Pt B, pp. 4880-4889, 2018.
R. W. Frenck, Belshe, R., Brady, R. C., Winokur, P. L., Campbell, J. D., Treanor, J., Hay, C. M., Dekker, C. L., Walter, E. B., Cate, T. R., Edwards, K. M., Hill, H., Wolff, M., Leduc, T., and Tornieporth, N., Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults., Vaccine, vol. 29, no. 34, pp. 5666-74, 2011.
R. W. Frenck, Jr, Belshe, R., Brady, R. C., Winokur, P. L., Campbell, J. D., Treanor, J., Hay, C. M., Dekker, C. L., Walter, Jr., E. B., TR, C., KM, E., Hill, H., Wolff, M., Leduc, T., and Tornieporth, N., Comparison of the Immunogenicity and Safety of a Split-Virion, Inactivated, Trivalent Influenza Vaccine (Fluzone®) Administered by Intradermal and Intramuscular Route in Healthy Adults, Vaccine, vol. 29, pp. 5666-5674, 2011.